Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery

Jazz Pharmaceuticals (JAZZ) acquired Actio Biosciences for $820M, adding epilepsy drug ABS-1230 to its pipeline. Jazz reported record Q2 revenue of $1.2B and raised 2026 guidance to $4.6B-$4.75B. The deal adds to existing debt, and ABS-1230 is in early clinical stages. Jazz's shares trade at a forward P/E of 11.03.

Jazz Pharmaceuticals (JAZZ) completed its $820M acquisition of Actio Biosciences, adding ABS-1230, a clinical-stage therapy for KCNT1-related epilepsy. Actio is now a subsidiary, strengthening Jazz's epilepsy pipeline. ABS-1230 has FDA designations and showed seizure reduction in early trials. Jazz plans to advance the therapy's development.

UBS raised its price target for Jazz Pharmaceuticals (JAZZ) to $337 from $315, citing the recent approval of Ziihera and potential for additional indications. The stock has surged 87% over the past year. Other analysts have also increased their price targets, with Jazz's management raising Ziihera's peak sales outlook to $3B-$5B.

Jazz Pharmaceuticals (JAZZ) received FDA approval for Ziihera-based regimens for HER2-positive gastroesophageal cancer, supported by Phase 3 data. This expands its oncology portfolio but also adds debt. Analysts forecast $5.7B revenue and $1.7B earnings by 2029, with a 17% upside potential. The company faces risks from patent cliffs and competition.

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy showed a statistically significant overall survival benefit over trastuzumab in the Phase 3 HERIZON-GEA-01 trial. The study involved 914 patients across 30+ countries. The FDA approved Ziihera for first-line treatment of HER2-positive gastroesophageal adenocarcinoma, providing a commercial pathway. However, the magnitude of the survival benefit and safety concerns remain key factors for adoption.

Jazz Pharmaceuticals (JAZZ) shares fell 6.9% since its last earnings report. Q2 2026 adjusted EPS missed estimates at $5.71, but revenues rose 16% YoY to $1.21B, beating expectations. The company raised 2026 revenue guidance to $4.60-$4.75B. Xywav sales grew 13% YoY, while Xyrem sales declined 14% YoY. Oncology sales increased 32% YoY, driven by Zepzelca's 42% growth.